![c[Arg-Arg-Arg-Arg-Nal-Nal-Nal]](https://file.medchemexpress.com/product_pic/hy-p3349.gif "Click to View c[Arg-Arg-Arg-Arg-Nal-Nal-Nal] Product Detail")
![c[Arg-Arg-Arg-Arg-Dip-Dip-Dip]](https://file.medchemexpress.com/product_pic/hy-p3348.gif "Click to View c[Arg-Arg-Arg-Arg-Dip-Dip-Dip] Product Detail")
Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
15 Results for "
ATCC 29213
" in MedChemExpress (MCE) Product Catalog:
Products (15)
15 Results for "ATCC 29213" in MCE Product Catalog:
Cat. No.: HY-150331
CAS No.: 635681-64-0
Target:
Research Areas:
DNA ligase-IN-2 (compound 2) is a potent LigA inhibitor and inhibits the DNA-independent autoadenylation activity of both full-length LigA and a truncated enzyme, LigA:AD (IC50=29 nM). DNA ligase-IN-2 effectively inhibits the growth of Staphylococcus aureus in vitro, with MIC valuse of 1, 1, and >64 μg/mL for S. aureus ATCC 29213, S. aureus ATCC 700699 and E. coli ATCC 25922, respectively .
Cat. No.: HY-178949
Target:
Research Areas:
MRSA antibiotic 3 (Compound C8) is a small-molecule antibiotic active against Methicillin (HY-121544)-resistant Staphylococcus aureus (MRSA), showing a MIC of 0.5 μg/mL against the standard S. aureus strain (ATCC 29213). MRSA antibiotic 3 potently inhibits the ATPase activity of S. aureus DNA gyrase with an IC50 of 0.32 μM. MRSA antibiotic 3 exhibits strong inhibitory activity against five clinical MRSA isolates, with MIC values ranging from 0.5 to 1 μg/mL. MRSA antibiotic 3 demonstrates negligible cytotoxicity at effective antibacterial concentrations and causes no hemolysis in erythrocytes even at extremely high concentrations. MRSA antibiotic 3 shows significant protective effects in both Galleria mellonella infection and murine sepsis models .
Cat. No.: HY-147546
CAS No.: 2454636-44-1
Antibacterial agent 107 (compound 14) is a potent antibacterial agent. Antibacterial agent 107 shows potent antibacterial activity against Gram-positive bacteria, with a MIC of 1.56 μg/mL (MRSA). Antibacterial agent 107 exhibits low hemolytic activity, high membrane selectivity, and rapid bactericidal activity. Antibacterial agent 107 shows effective in vivo efficacy in the murine model of bacterial keratitis caused by Staphylococcus aureus ATCC29213 .
Cat. No.: HY-169571
CAS No.: 430444-03-4
Antimicrobial agent-38 (compound 10) is a potent inhibitor of methicillin-resistant S. aureus strain ATCC 700699 and nonresistant strain ATCC 29213, with MICs of 32 and 64 mg/L .
Cat. No.: HY-P5638
CAS No.: 2268718-85-8
Cat. No.: HY-P3349
CAS No.: 2619854-01-0
Cat. No.: HY-P3348
CAS No.: 2619853-87-9
Cat. No.: HY-161827
CAS No.: 3050586-22-3
Anti-MRSA agent 14 (Compound C17) has antibacterial agent against MRSA and MRSA-infected skin murine model. Anti-MRSA agent 14 is more potential than Norfloxacin (HY-B0132) against MRSA. Anti-MRSA agent 14 disrupts cell membrane and restrains metabolism. Anti-MRSA agent 14 shows antibacterial effects against S. aureus ATCC 6538, S. aureus ATCC 29213, S. epidermidis ATCC 12228, and MRSA with MIC values of 1, 2, 2, 1 μM respectively .
Cat. No.: HY-179059
Research Areas:
Anti-MRSA agent 40 (Compound 7-8) is a potent agent against Methicillin-resistant Staphylococcus aureus (MRSA). Anti-MRSA agent 40 exhibits significant antibacterial activity against MRSA2 and S. aureus ATCC 29213, with its MIC values being 1 μg/mL. Anti-MRSA agent 40 causes depolarization of the cell membrane, damages membrane integrity, and simultaneously increases the level of ROS within MRSA2, ultimately leading to cell lysis and death. Anti-MRSA agent 40 shows significant efficacy in the MRSA2 skin abscess model. Anti-MRSA agent 40 can be used for research on anti-MRSA infections .
Cat. No.: HY-172390
CAS No.: 2975141-09-2
Florfenicol-propanoate-piperidin (Compound 1) is the derivative of Florfenicol (HY-B1374). Florfenicol-propanoate-piperidin exhibits antibacterial activity, inhibits E. coli ATCC25922, Salmonella CICC110420, S. aureus ATCC29213, B. subtilis CMCC(B)63501, E. faecalis ATCC29212, S. suis CVCC606, and Haemophilus parasuis with MIC of 2-8 μM .
Cat. No.: HY-N16443
CAS No.: 915403-42-8
Category:
Target:
Cat. No.: HY-187561
Antibacterial agent 365 is a benzothiazole-based antibacterial agent that primarily exerts its effects by disrupting bacterial cell membranes. Antibacterial agent 365 exhibits a MIC of 4 μg/mL against Staphylococcus aureus ATCC 29213, MRSA ATCC BAA41 and MRSA ATCC 43300. Antibacterial agent 365 can be used in studies of MRSA infection, bacterial cell membrane disruption, biofilm formation and antimicrobial resistance .
Cat. No.: HY-175987
Antimycobacterial agent-12 (Compound Ec42), a derivative of Platensimycin (HY-127146), is a dual-functional inhibitor KasA and KasB. Antimycobacterial agent-12 has antibacterial activity with a MICs of 2, 2 and 4 μg/mL against Staphylococcus aureus ATCC 29213, Mycobacterium smegmatis and its Isoniazid (HY-B0329)-resistant strain, respectively. Antimycobacterial agent-12 has a superior antimycobacterial activity in M. smegmatis-infected mouse models. Antimycobacterial agent-12 can be used for tuberculosis research .
Cat. No.: HY-168729
CAS No.: 3052804-28-8
Antibacterial agent 256 (Compound C09) is an inhibitor for type I signal peptidase (SPase I). Antibacterial agent 256 inhibits gram-positive bacteria, that inhibits S. aureus ATCC 29213, E. faecium QF31, E. faecalis SF23-1 and S. suis P1/7, with MIC of 1-16 μg/mL. Antibacterial agent 256 exhibits cytotoxicity in cancer cell HEp-2 and Caco-2 with CC50 of 14.65 μg/mL and 21.93 μg/mL. Antibacterial agent 256 exhibits a hemolytic activity on mouse RBCs, with an HC50 of 13.29 μg/mL. Antibacterial agent 256 ameliorates the MRSA skin infection in mouse model .
Cat. No.: HY-180767
Target:
Azithromycin-amide-C3-amide-quinoxaline (Compound 5f) is an Azithromycin (HY-17506) derivative and antibacterial agent. Azithromycin-amide-C3-amide-quinoxaline inhibits topoisoisomerase I with an IC50 of 120.7 μM. Azithromycin-amide-C3-amide-quinoxaline interacts with 70S E. coli ribosome with a Kd of 0.8 nM. Azithromycin-amide-C3-amide-quinoxaline inhibits bacterial translation with an IC50 of 0.7 μM. Azithromycin-amide-C3-amide-quinoxaline shows antibacterial potency against S. pneumonia ATCC 49619, S. aureus ATCC 29213, E. faecalis ATCC 29212 with MICs of 0.06 μg/mL, 2 μg/mL, 0.5 μg/mL, respectively. Azithromycin-amide-C3-amide-quinoxaline exhibits anticancer activity against prostate cancer, colon cancer .
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
